Cross-national harmonization of cognitive measures across HRS HCAP (USA) and LASI-DAD (India).

Autor: Jet M J Vonk, Alden L Gross, Andrea R Zammit, Laiss Bertola, Justina F Avila, Roos J Jutten, Leslie S Gaynor, Claudia K Suemoto, Lindsay C Kobayashi, Megan E O'Connell, Olufisayo Elugbadebo, Priscilla A Amofa, Adam M Staffaroni, Miguel Arce Rentería, Indira C Turney, Richard N Jones, Jennifer J Manly, Jinkook Lee, Laura B Zahodne

Publikováno v: PLoS ONE, Vol 17, Iss 2, p e0264166 (2022)

BackgroundAs global populations age, cross-national comparisons of cognitive health and dementia risk are increasingly valuable. It remains unclear, however, whether country-level differences in cognitive function are attributable to population diffe

Externí odkaz: https://doaj.org/article/bc8bc0a0d475448b8f2dfef917838382

Identifying longitudinal cognitive resilience from cross-sectional amyloid, tau, and neurodegeneration

Autor: Rory Boyle, Diana L. Townsend, Hannah M. Klinger, Catherine E. Scanlon, Ziwen Yuan, Gillian T. Coughlan, Mabel Seto, Zahra Shirzadi, Wai-Ying Wendy Yau, Roos J. Jutten, Christoph Schneider, Michelle E. Farrell, Bernard J. Hanseeuw, Elizabeth C. Mormino, Hyun-Sik Yang, Kathryn V. Papp, Rebecca E. Amariglio, Heidi I. L. Jacobs, Julie C. Price, Jasmeer P. Chhatwal, Aaron P. Schultz, Michael J. Properzi, Dorene M. Rentz, Keith A. Johnson, Reisa A. Sperling, Timothy J. Hohman, Michael C. Donohue, Rachel F. Buckley, for the Alzheimer’s Disease Neuroimaging Initiative

Publikováno v: Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-16 (2024)

Abstract Background Leveraging Alzheimer’s disease (AD) imaging biomarkers and longitudinal cognitive data may allow us to establish evidence of cognitive resilience (CR) to AD pathology in-vivo. Here, we applied latent class mixture modeling, adju

Externí odkaz: https://doaj.org/article/533e6b89a4fd4deeb58b8bf4d29de93c

Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum

Autor: Mark A. Dubbelman, Roos J. Jutten, Sarah E. Tomaszewski Farias, Rebecca E. Amariglio, Rachel F. Buckley, Pieter Jelle Visser, Dorene M. Rentz, Keith A. Johnson, Michael J. Properzi, Aaron Schultz, Nancy Donovan, Jennifer R. Gatchell, Charlotte E. Teunissen, Bart N. M. Van Berckel, Wiesje M. Van der Flier, Reisa A. Sperling, Kathryn V. Papp, Philip Scheltens, Gad A. Marshall, Sietske A. M. Sikkes, for the Alzheimer Disease Neuroimaging Initiative, National Alzheimer’s Coordinating Center, the Harvard Aging Brain Study, the Alzheimer Dementia Cohort

Publikováno v: Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-11 (2020)

Abstract Background Impairment in daily functioning is a clinical hallmark of dementia. Difficulties with “instrumental activities of daily living” (IADL) seem to increase gradually over the course of Alzheimer’s disease (AD), before dementia o

Externí odkaz: https://doaj.org/article/89c52c5343444b7788cbea71dd84912f

Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease

Autor: Roos J. Jutten, Kathryn V. Papp, Suzanne Hendrix, Noel Ellison, Jessica B. Langbaum, Michael C. Donohue, Jason Hassenstab, Paul Maruff, Dorene M. Rentz, John Harrison, Jeffrey Cummings, Philip Scheltens, Sietske A. M. Sikkes

Publikováno v: Alzheimer's & dementia : the journal of the Alzheimer's Association, 19(2), 708-720. Elsevier Inc.
Jutten, R J, Papp, K V, Hendrix, S, Ellison, N, Langbaum, J B, Donohue, M C, Hassenstab, J, Maruff, P, Rentz, D M, Harrison, J, Cummings, J, Scheltens, P & Sikkes, S A M 2023, ' Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease ', Alzheimer's & dementia : the journal of the Alzheimer's Association, vol. 19, no. 2, pp. 708-720 . https://doi.org/10.1002/alz.12773
Jutten, R J, Papp, K V, Hendrix, S, Ellison, N, Langbaum, J B, Donohue, M C, Hassenstab, J, Maruff, P, Rentz, D M, Harrison, J, Cummings, J, Scheltens, P & Sikkes, S A M 2022, ' Why a clinical trial is as good as its outcome measure : A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease ', Alzheimer's and Dementia . https://doi.org/10.1002/alz.12773
Alzheimer's and Dementia. Elsevier

A crucial aspect of any clinical trial is using the right outcome measure to assess treatment efficacy. Compared to the rapidly evolved understanding and measurement of pathophysiology in preclinical and early symptomatic stages of Alzheimer's diseas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8bf06a7f99623b61f39e9e38dcdfb95
https://hdl.handle.net/1871.1/b4f29ac0-3e5b-4a86-9736-70999cc43de9

Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire

Autor: Roos J. Jutten, Carel F.W. Peeters, Sophie M.J. Leijdesdorff, Pieter Jelle Visser, Andrea B. Maier, Caroline B. Terwee, Philip Scheltens, Sietske A.M. Sikkes

Publikováno v: Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 8, Iss 1, Pp 26-35 (2017)

Abstract Introduction Detecting functional decline from normal aging to dementia is relevant for diagnostic and prognostic purposes. Therefore, the Amsterdam IADL Questionnaire (A‐IADL‐Q) was developed: a 70‐item proxy‐based tool with good ps

Externí odkaz: https://doaj.org/article/05a4e540b66e4125957203ee0ba4bbe9